Abstract
Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good toler-ability and treatment response at 6 months.
Cite
CITATION STYLE
APA
Hewison, C., Ferlazzo, G., Avaliani, Z., Hayrapetyan, A., Jonckheere, S., Khaidarkhanova, Z., … Varaine, F. (2017, October 1). Six-month response to delamanid treatment in MDR TB patients. Emerging Infectious Diseases. Centers for Disease Control and Prevention (CDC). https://doi.org/10.3201/eid2310.170468
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free